FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3049643238> ?p ?o ?g. }

• W3049643238 endingPage "2180.e6" @default.
• W3049643238 startingPage "2163" @default.
• W3049643238 abstract "Background & AimsMutant KRAS promotes glutaminolysis, a process that uses steps from the tricarboxylic cycle to convert glutamine to α-ketoglutarate and other molecules via glutaminase and SLC25A22. This results in inhibition of demethylases and epigenetic alterations in cells that increase proliferation and stem cell features. We investigated whether mutant KRAS-mediated glutaminolysis affects the epigenomes and activities of colorectal cancer (CRC) cells.MethodsWe created ApcminKrasG12D mice with intestine-specific knockout of SLC25A22 (ApcminKrasG12DSLC25A22fl/fl mice). Intestine tissues were collected and analyzed by histology, immunohistochemistry, and DNA methylation assays; organoids were derived and studied for stem cell features, along with organoids derived from 2 human colorectal tumor specimens. Colon epithelial cells (1CT) and CRC cells (DLD1, DKS8, HKE3, and HCT116) that expressed mutant KRAS, with or without knockdown of SLC25A22 or other proteins, were deprived of glutamine or glucose and assayed for proliferation, colony formation, glucose or glutamine consumption, and apoptosis; gene expression patterns were analyzed by RNA sequencing, proteins by immunoblots, and metabolites by liquid chromatography–mass spectrometry, with [U-13C5]-glutamine as a tracer. Cells and organoids with knocked down, knocked out, or overexpressed proteins were analyzed for DNA methylation at CpG sites using arrays. We performed immunohistochemical analyses of colorectal tumor samples from 130 patients in Hong Kong (57 with KRAS mutations) and Kaplan-Meier analyses of survival. We analyzed gene expression levels of colorectal tumor samples in The Cancer Genome Atlas.ResultsCRC cells that express activated KRAS required glutamine for survival, and rapidly incorporated it into the tricarboxylic cycle (glutaminolysis); this process required SLC25A22. Cells incubated with succinate and non-essential amino acids could proliferate under glutamine-free conditions. Mutant KRAS cells maintained a low ratio of α-ketoglutarate to succinate, resulting in reduced 5-hydroxymethylcytosine—a marker of DNA demethylation, and hypermethylation at CpG sites. Many of the hypermethylated genes were in the WNT signaling pathway and at the protocadherin gene cluster on chromosome 5q31. CRC cells without mutant KRAS, or with mutant KRAS and knockout of SLC25A22, expressed protocadherin genes (PCDHAC2, PCDHB7, PCDHB15, PCDHGA1, and PCDHGA6)—DNA was not methylated at these loci. Expression of the protocadherin genes reduced WNT signaling to β-catenin and expression of the stem cell marker LGR5. ApcminKrasG12DSLC25A22fl/fl mice developed fewer colon tumors than ApcminKrasG12D mice (P < .01). Organoids from ApcminKrasG12DSLC25A22fl/fl mice had reduced expression of LGR5 and other markers of stemness compared with organoids derived from ApcminKrasG12D mice. Knockdown of SLC25A22 in human colorectal tumor organoids reduced clonogenicity. Knockdown of lysine demethylases, or succinate supplementation, restored expression of LGR5 to SLC25A22-knockout CRC cells. Knockout of SLC25A22 in CRC cells that express mutant KRAS increased their sensitivity to 5-fluorouacil. Level of SLC25A22 correlated with levels of LGR5, nuclear β-catenin, and a stem cell-associated gene expression pattern in human colorectal tumors with mutations in KRAS and reduced survival times of patients.ConclusionsIn CRC cells that express activated KRAS, SLC25A22 promotes accumulation of succinate, resulting in increased DNA methylation, activation of WNT signaling to β-catenin, increased expression of LGR5, proliferation, stem cell features, and resistance to 5-fluorouacil. Strategies to disrupt this pathway might be developed for treatment of CRC. Mutant KRAS promotes glutaminolysis, a process that uses steps from the tricarboxylic cycle to convert glutamine to α-ketoglutarate and other molecules via glutaminase and SLC25A22. This results in inhibition of demethylases and epigenetic alterations in cells that increase proliferation and stem cell features. We investigated whether mutant KRAS-mediated glutaminolysis affects the epigenomes and activities of colorectal cancer (CRC) cells. We created ApcminKrasG12D mice with intestine-specific knockout of SLC25A22 (ApcminKrasG12DSLC25A22fl/fl mice). Intestine tissues were collected and analyzed by histology, immunohistochemistry, and DNA methylation assays; organoids were derived and studied for stem cell features, along with organoids derived from 2 human colorectal tumor specimens. Colon epithelial cells (1CT) and CRC cells (DLD1, DKS8, HKE3, and HCT116) that expressed mutant KRAS, with or without knockdown of SLC25A22 or other proteins, were deprived of glutamine or glucose and assayed for proliferation, colony formation, glucose or glutamine consumption, and apoptosis; gene expression patterns were analyzed by RNA sequencing, proteins by immunoblots, and metabolites by liquid chromatography–mass spectrometry, with [U-13C5]-glutamine as a tracer. Cells and organoids with knocked down, knocked out, or overexpressed proteins were analyzed for DNA methylation at CpG sites using arrays. We performed immunohistochemical analyses of colorectal tumor samples from 130 patients in Hong Kong (57 with KRAS mutations) and Kaplan-Meier analyses of survival. We analyzed gene expression levels of colorectal tumor samples in The Cancer Genome Atlas. CRC cells that express activated KRAS required glutamine for survival, and rapidly incorporated it into the tricarboxylic cycle (glutaminolysis); this process required SLC25A22. Cells incubated with succinate and non-essential amino acids could proliferate under glutamine-free conditions. Mutant KRAS cells maintained a low ratio of α-ketoglutarate to succinate, resulting in reduced 5-hydroxymethylcytosine—a marker of DNA demethylation, and hypermethylation at CpG sites. Many of the hypermethylated genes were in the WNT signaling pathway and at the protocadherin gene cluster on chromosome 5q31. CRC cells without mutant KRAS, or with mutant KRAS and knockout of SLC25A22, expressed protocadherin genes (PCDHAC2, PCDHB7, PCDHB15, PCDHGA1, and PCDHGA6)—DNA was not methylated at these loci. Expression of the protocadherin genes reduced WNT signaling to β-catenin and expression of the stem cell marker LGR5. ApcminKrasG12DSLC25A22fl/fl mice developed fewer colon tumors than ApcminKrasG12D mice (P < .01). Organoids from ApcminKrasG12DSLC25A22fl/fl mice had reduced expression of LGR5 and other markers of stemness compared with organoids derived from ApcminKrasG12D mice. Knockdown of SLC25A22 in human colorectal tumor organoids reduced clonogenicity. Knockdown of lysine demethylases, or succinate supplementation, restored expression of LGR5 to SLC25A22-knockout CRC cells. Knockout of SLC25A22 in CRC cells that express mutant KRAS increased their sensitivity to 5-fluorouacil. Level of SLC25A22 correlated with levels of LGR5, nuclear β-catenin, and a stem cell-associated gene expression pattern in human colorectal tumors with mutations in KRAS and reduced survival times of patients. In CRC cells that express activated KRAS, SLC25A22 promotes accumulation of succinate, resulting in increased DNA methylation, activation of WNT signaling to β-catenin, increased expression of LGR5, proliferation, stem cell features, and resistance to 5-fluorouacil. Strategies to disrupt this pathway might be developed for treatment of CRC." @default.
• W3049643238 created "2020-08-21" @default.
• W3049643238 creator A5011601417 @default.
• W3049643238 creator A5013202799 @default.
• W3049643238 creator A5043200557 @default.
• W3049643238 creator A5044395307 @default.
• W3049643238 creator A5047411423 @default.
• W3049643238 creator A5049274840 @default.
• W3049643238 creator A5049775236 @default.
• W3049643238 creator A5067832646 @default.
• W3049643238 creator A5069893086 @default.
• W3049643238 creator A5071901988 @default.
• W3049643238 creator A5072676408 @default.
• W3049643238 creator A5073800642 @default.
• W3049643238 creator A5075793775 @default.
• W3049643238 creator A5076016269 @default.
• W3049643238 creator A5085099069 @default.
• W3049643238 creator A5091752994 @default.
• W3049643238 date "2020-12-01" @default.
• W3049643238 modified "2023-10-16" @default.
• W3049643238 title "In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance" @default.
• W3049643238 cites W1680709572 @default.
• W3049643238 cites W1992372073 @default.
• W3049643238 cites W2012588998 @default.
• W3049643238 cites W2066362124 @default.
• W3049643238 cites W2067299927 @default.
• W3049643238 cites W2090562908 @default.
• W3049643238 cites W2092812546 @default.
• W3049643238 cites W2104852749 @default.
• W3049643238 cites W2125218830 @default.
• W3049643238 cites W2155503224 @default.
• W3049643238 cites W2485679354 @default.
• W3049643238 cites W2513105811 @default.
• W3049643238 cites W2560017000 @default.
• W3049643238 cites W2569086487 @default.
• W3049643238 cites W2795867722 @default.
• W3049643238 cites W2891671374 @default.
• W3049643238 cites W2973444726 @default.
• W3049643238 cites W4247739888 @default.
• W3049643238 doi "https://doi.org/10.1053/j.gastro.2020.08.016" @default.
• W3049643238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32814111" @default.
• W3049643238 hasPublicationYear "2020" @default.
• W3049643238 type Work @default.
• W3049643238 sameAs 3049643238 @default.
• W3049643238 citedByCount "68" @default.
• W3049643238 countsByYear W30496432382021 @default.
• W3049643238 countsByYear W30496432382022 @default.
• W3049643238 countsByYear W30496432382023 @default.
• W3049643238 crossrefType "journal-article" @default.
• W3049643238 hasAuthorship W3049643238A5011601417 @default.
• W3049643238 hasAuthorship W3049643238A5013202799 @default.
• W3049643238 hasAuthorship W3049643238A5043200557 @default.
• W3049643238 hasAuthorship W3049643238A5044395307 @default.
• W3049643238 hasAuthorship W3049643238A5047411423 @default.
• W3049643238 hasAuthorship W3049643238A5049274840 @default.
• W3049643238 hasAuthorship W3049643238A5049775236 @default.
• W3049643238 hasAuthorship W3049643238A5067832646 @default.
• W3049643238 hasAuthorship W3049643238A5069893086 @default.
• W3049643238 hasAuthorship W3049643238A5071901988 @default.
• W3049643238 hasAuthorship W3049643238A5072676408 @default.
• W3049643238 hasAuthorship W3049643238A5073800642 @default.
• W3049643238 hasAuthorship W3049643238A5075793775 @default.
• W3049643238 hasAuthorship W3049643238A5076016269 @default.
• W3049643238 hasAuthorship W3049643238A5085099069 @default.
• W3049643238 hasAuthorship W3049643238A5091752994 @default.
• W3049643238 hasBestOaLocation W30496432381 @default.
• W3049643238 hasConcept C104317684 @default.
• W3049643238 hasConcept C114851261 @default.
• W3049643238 hasConcept C121608353 @default.
• W3049643238 hasConcept C137620995 @default.
• W3049643238 hasConcept C143065580 @default.
• W3049643238 hasConcept C185592680 @default.
• W3049643238 hasConcept C2778160063 @default.
• W3049643238 hasConcept C2781187634 @default.
• W3049643238 hasConcept C502942594 @default.
• W3049643238 hasConcept C526805850 @default.
• W3049643238 hasConcept C54355233 @default.
• W3049643238 hasConcept C55493867 @default.
• W3049643238 hasConcept C62478195 @default.
• W3049643238 hasConcept C71924100 @default.
• W3049643238 hasConcept C86803240 @default.
• W3049643238 hasConcept C96232424 @default.
• W3049643238 hasConceptScore W3049643238C104317684 @default.
• W3049643238 hasConceptScore W3049643238C114851261 @default.
• W3049643238 hasConceptScore W3049643238C121608353 @default.
• W3049643238 hasConceptScore W3049643238C137620995 @default.
• W3049643238 hasConceptScore W3049643238C143065580 @default.
• W3049643238 hasConceptScore W3049643238C185592680 @default.
• W3049643238 hasConceptScore W3049643238C2778160063 @default.
• W3049643238 hasConceptScore W3049643238C2781187634 @default.
• W3049643238 hasConceptScore W3049643238C502942594 @default.
• W3049643238 hasConceptScore W3049643238C526805850 @default.
• W3049643238 hasConceptScore W3049643238C54355233 @default.
• W3049643238 hasConceptScore W3049643238C55493867 @default.
• W3049643238 hasConceptScore W3049643238C62478195 @default.
• W3049643238 hasConceptScore W3049643238C71924100 @default.
• W3049643238 hasConceptScore W3049643238C86803240 @default.
• W3049643238 hasConceptScore W3049643238C96232424 @default.

• next